NEO6860, modality-selective TRPV1 antagonist: A randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain

Keyphrases

• Placebo 100%
• Knee Osteoarthritis 100%
• Proof of Concept Study 100%
• Naproxen 100%
• Knee Pain 100%
• TRPV1 Antagonist 100%
• Pain Intensity 60%
• Adverse Events 40%
• Analgesic 40%
• Dizziness 20%
• Confidence Interval 20%
• Pain Level 20%
• Numerical Rating Scale 20%
• Body Temperature 20%
• Hypoesthesia 20%
• Headache 20%
• Increased Blood Pressure 20%
• Twice a Day 20%
• Analgesic Efficacy 20%
• Safety Profile 20%
• Phase II Study 20%
• First Dose 20%
• Body Heat 20%
• 2-dose 20%
• Least Mean Square 20%
• Synergism 20%
• Nausea 20%
• Staircase Test 20%
• Oral Dosing 20%
• Interval Change 20%
• Heat Pain Perception 20%
• Relieve Pain 20%
• Kellgren-Lawrence 20%
• Capsaicin 20%

Medicine and Dentistry

• Osteoarthritis 100%
• Placebo 100%
• Naproxen 100%
• Vanilloid Receptor 1 Antagonist 100%
• Knee Pain 100%
• Adverse Event 40%
• Dizziness 20%
• Nociception 20%
• Least Square Analysis 20%
• Numeric Rating Scale 20%
• Headache 20%
• Hypoesthesia 20%
• Elevated Blood Pressure 20%
• Analgesic Efficacy 20%
• Nausea 20%
• Capsaicin 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Osteoarthritis 100%
• Placebo 100%
• Naproxen 100%
• Knee Pain 100%
• Vanilloid Receptor 1 Antagonist 100%
• Analgesic Agent 60%
• Adverse Event 40%
• Dizziness 20%
• Headache 20%
• Synergism 20%
• Nausea 20%
• Hypoesthesia 20%
• Elevated Blood Pressure 20%
• Capsaicin 20%